Connect with us

BioPharma

VirExit Technologies Inc (OTCMKTS: VXIT) Steady Rise Northbound as PPE Innovator Launches the VirExit BreatheEasyMask using LIVINGUARD® Technology

Published

on

VirExit Technologies Inc (OTCMKTS: VXIT) has been on the move northbound in recent trading on a significant surge in volume as speculators jump on board bidding the stock higher. VXIT is quickly gaining the attention of small cap investors with some pretty big players jumping on board in recent days. VXIT already has ready liquidity as PVDG was a heavily traded stock and we wrote about the Company as James C. Katzaroff became new majority owner and initiated an aggressive plan of action to go “pink current” (followed by an audit and possibly up listing again to OTCQB) and become a leader in Virus detection, UV Virus Destruction and PPE. Mr. Katzaroff has maintained he will stop any new conversations happening and has implemented a no reverse split policy. VXIT has ready liquidity, a fast growing shareholder base, upward momentum and a significant gap to fill. 

VXIT is an exciting story in small caps that is getting the attention of penny stock speculators as the Company makes big moves in Virus detection, UV Virus Destruction and PPE. The Company has made 2 important acquisitions starting with Virexit, a licensing company specializing in the antimicrobial and antiviral sectors followed by the acquisition of Safer Place Technologies™ a Company focused on the flight to safety, that has identified state-of-the-art technologies that can be combined, in various configurations, to create safer business locations, public location environments, as well as safer households. The Company is led by new majority shareholder and CEO James C. Katzaroff who served on the board and was a Managing Director at Smi Capital Markets LLC., which operates a US based Brokerage Firm and has done $50 billion in transactions. Recently the Company. Recently VirExit launched the new VirExit BreatheEasyMask™ made by the Company’s partner; Fine Guard® using the LIVINGUARD® patented technology. Known as one of the world’s most protective masks, at 98-99% effective, it is also one of the most comfortable on the market today. Fine Guard’s LIVINGUARD fabric used in the VirExit BreatheEasyMask is endorsed by a significant number of organizations including Product Safety Labs, The Medical Wellness Association, Freie Universitaet Berlin, The University of Arizona, and the Government of Singapore. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

VirExit Technologies Inc (OTCMKTS: VXIT) operating out of Richland, Washington, has designed a proprietary, full-service program that promotes all aspects of wellbeing, productivity, safety, and creativity. The Company has been growing through acquisition acquiring the registered brand, Virexit, along with other related intellectual property owned and developed by marketing expert, Patrick Netter in 2020. The Virexit brand pioneers innovative, effective, ethical, and safe products within the antiviral space. Also, during 2020, VXIT purchased Safer Place Technologies, LLC, whose purpose is to create a primary sales and marketing platform as a vertical online marketplace. This new acquisition seeks to provide a single source for buyers and sellers of protective products and services which resonate with the Virexit mission statement: Making the world a safer place with innovative, ethical and effective technologies. VSure, VirExit’s latest undertaking focuses on certification and implementation. That portal is scheduled to launch in the first half of 2022. 

The Company is starting to get some media attention and was recently featured on USA Today’s America Reopened special section. VirExit, The VLife, The SaferPlace Market and VXIT other brands were highlighted in the guide online and in print.  

VirExit launched its proprietary wellness, health and safety portal, entitled The VLife. The portal focuses on both corporations and consumers. Experts on this heavily content-driven site will address numerous aspects of today’s greatest challenges: returning to work safely, maintaining a mindful and productive state, and the effective exercising of safety precautions. The website, called The VLife (www.thevlife.net), focuses on a variety of areas where many of the current and soon-to-be products on the SaferPlace Market will work in tandem with the content. The Company has designed a full-service program, with high value content including video blogs, designed to promote wellbeing, productivity, and creativity. The portal is the second phase of VirExit’s three-pronged approach to the future. VirExit will be announcing its third offering shortly.  

VirExit’s Safer Place Market offers certified products focused on health, safety, and wellness.  Our vertical-based concierges understands the needs of your company, school, or home experience. VirExit’s wellness products are designed to bring balance to your life while enhancing day. From seated treadmills to nutraceuticals to boutique style custom candles, look no further than the Safer Place online market. VXIThas partnered with Fine Hygienic Holding to carry a variety of different wellness products including personal protective equipment (PPE) and nutritional supplements to be sold in the SaferPlace.Market and TheVLife.store. Both companies share the same goal: empowering our return to a pre-COVID lifestyle, while making an impact in business, communities, and serving humanity in positive ways. 

https://twitter.com/OtcRunner1/status/1486003212821827584

https://twitter.com/jimmy_otc/status/1485070609751105539

To Find out the inside Scoop on VXIT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

VXIT

VXIT has assembled a powerhouse management team led by majority shareholder and CEO James C. Katzaroff. Mr. Katzaroff is a seasoned executive highly regarded internationally for his proven expertise in corporate engineering as well as developing and implementing impactful senior-level corporate strategy. Mr. Katzaroff was hired straight out of college as a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Mr. Katzaroff was also on the board and Managing Director at Smi Capital Markets LLC., which operates a US based Brokerage Firm and has done $50 billion in transactions. Mr. Katzaroff is passionate about fostering critical investment banking and private investor relationships as well as managing intricate stakeholder relationships. Associates and clients continue to trust Mr. Katzaroff with their most critical business needs because of his passion, commitment and proven ability to be a solution provider and create win-win outcomes to the most complex issues that challenge all growth companies. Patrick Netter will be spearheading the Company’s advertising and public relations strategy. Peter Thusat is the Managing Director of New Product and Service Vetting.  

VirExit is targeting the booming personal protective equipment market that has seen rapid growth in the face of covid, market size is expected to reach USD 112.07 billion by 2028, registering a CAGR of 7.3% over the forecast period, according to a new report by Grand View Research, Inc. The stringent regulations imposed by the U.S. Department of Labor and Occupational Safety and Health Administration (OSHA) in the country have a positive impact on product demand from the end-use industries. In addition, the growing employee awareness related to personal safety has a significant influence on the increased penetration of personal protective equipment (PPE) in the country. 

On November 16, 2021 VXIT announced it is launching the new VirExit BreatheEasyMask™ at the industry’s largest aeronautical event. The VirExit BreatheEasyMask hosts trademark 907122550 and is made by Fine Guard® using the LIVINGUARD® patented technology. Known as one of the world’s most protective masks, at 98-99% effective, it is also one of the most comfortable on the market today. Fine Guard’s LIVINGUARD fabric used in the VirExit BreatheEasyMask is endorsed by a significant number of organizations including Product Safety Labs, The Medical Wellness Association, Freie Universitaet Berlin, The University of Arizona, and the Government of Singapore. 

The VirExit team of professionals, including the Company’s top health advisors, are currently evaluating a variety of additional products that will be onboarded regularly to its sites. The VirExit BreatheEasyMask by Fine Guard is available today on www.saferplace.market along with a variety of other health, safety, and wellness products. 

VXIT CEO James C. Katzaroff stated: “We are very excited to bring this mask to the market at a time when we can never be too careful. The airline industry is a perfect place to launch our mask, especially given the travel constraints due to COVID-19. We are thrilled that the APEX Expo is giving away over 1,500 of our masks to visitors and guests at the Expo, so that airline personnel, decision makers, and C-Level personnel will feel safer than ever before. It’s a tribute to the technology and to our global ability to rebound at a difficult time that makes this mask the traveler’s best choice.” 

Fine Guard® Masks with LIVINGUARD® Technology provide a better Solution to Virus Protection. Filtration Masks like N95 attempt to “filter” out viruses, thus making it difficult to breathe. LIVINGUARD® masks attract and destroys 99.9% of airborne viruses on contact. The result is the protection of the best filtering masks with a breathable mask. Passengers can comfortably wear all flight long, and …all day at their destination, and for 1 year of use back home. 

  • Fine HH can scale production volumes up across 3 plants, and can make up to 500,000 masks/day, 15 million per month, 180 million per year.
  • Since these masks are reusable, this means Fine Guard® is protecting an additional 500,000 people every day.
  • Fine HH was one of the first in the world with a reusable mask, and first with deactivation technology.
  • Fine Guard® sales were launched February 8, 2020 on Amazon. At one point, Fine HH was the leading reusable mask in the world.
  • Fine Guard® masks are sold in over 100 countries worldwide / over 10 million masks.
  • Fine HH has a global licensing agreement with LIVINGUARD® and has exclusivity to the technology in over 30 markets in the world.
  • Fine HH is the largest seller of LIVINGUARD®.

For More on VXIT Subscribe Right Now!

VXIT has been on the move northbound in recent trading on a significant surge in volume as speculators jump on board bidding the stock higher. VXIT is quickly gaining the attention of small cap investors with some pretty big players jumping on board in recent days. VXIT already has ready liquidity as PVDG was a heavily traded stock and we wrote about the Company as James C. Katzaroff became new majority owner and initiated an aggressive plan of action to go “pink current” (followed by an audit and possibly up listing again to OTCQB) and become a leader in Virus detection, UV Virus Destruction and PPE. Mr. Katzaroff has maintained he will stop any new conversations happening and has implemented a no reverse split policy. VXIT has ready liquidity, a fast growing shareholder base, upward momentum and a significant gap to fill. VXIT is an exciting story in small caps that is getting the attention of penny stock speculators as the Company makes big moves in Virus detection, UV Virus Destruction and PPE. The Company has made 2 important acquisitions starting with Virexit, a licensing company specializing in the antimicrobial and antiviral sectors followed by the acquisition of Safer Place Technologies™ a Company focused on the flight to safety, that has identified state-of-the-art technologies that can be combined, in various configurations, to create safer business locations, public location environments, as well as safer households. The Company is led by new majority shareholder and CEO James C. Katzaroff who served on the board and was a Managing Director at Smi Capital Markets LLC., which operates a US based Brokerage Firm and has done $50 billion in transactions. Recently the Company. Recently VirExit launched the new VirExit BreatheEasyMask™ made by the Company’s partner; Fine Guard® using the LIVINGUARD® patented technology. Known as one of the world’s most protective masks, at 98-99% effective, it is also one of the most comfortable on the market today. Fine Guard’s LIVINGUARD fabric used in the VirExit BreatheEasyMask is endorsed by a significant number of organizations including Product Safety Labs, The Medical Wellness Association, Freie Universitaet Berlin, The University of Arizona, and the Government of Singapore. We will be updating on VXIT when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VXIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VXIT either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.